Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.
It has been demonstrated that microRNAs (miRNAs) play an important role in the carcinogenesis of osteosarcoma. The aim of the present study was to determine the diagnostic and prognostic value of serum miR-124 in osteosarcoma. The serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR). The level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p< 0.05). The serum miR-124 levels in osteosarcoma patients were significantly elevated after receiving surgical treatment (p< 0.01). Furthermore, the area under the receiver-operating characteristic (ROC) curve (AUC) for serum miR-124 was 0.846, combining with 79.8% sensitivity and 86.00% specificity. A significant correlation was detected between serum miR-124 expression and distant metastasis (p= 0.0256) as well as clinical stage (p= 0.0006). Similarly, serum miR-124 levels in patients with advanced clinical stage or positive distant metastasis were significantly decreased. Moreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates. Finally, multivariate analysis revealed that serum miR-124 was an independent prognostic indicator for osteosarcoma. These findings suggested that serum miR-124 might be a promising biomarker with diagnostic and prognostic value for osteosarcoma.